Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study

Mise à jour : Il y a 4 ans
Référence : NCT00903331

Femme et Homme

Extrait

The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study objective is to demonstrate that macitentan positively affects the forced vital capacity (FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF). The secondary objectives are to evaluate the effect of macitentan on the time to disease worsening or death in patients with IPF, and to evaluate the benefit/risk profile of macitentan in the treatment of patients with IPF.


Critère d'inclusion

  • Idiopathic pulmonary fibrosis


Liens